• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

鉴定 SARS-CoV-2 诱导的通路揭示了药物再利用策略。

Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies.

机构信息

Milner Therapeutics Institute, University of Cambridge, Cambridge, UK.

Institute for Virology, FB10-Veterinary Medicine, Justus-Liebig University, Gießen 35392, Germany.

出版信息

Sci Adv. 2021 Jun 30;7(27). doi: 10.1126/sciadv.abh3032. Print 2021 Jun.

DOI:10.1126/sciadv.abh3032
PMID:34193418
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8245040/
Abstract

The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates the rapid development of new therapies against coronavirus disease 2019 (COVID-19) infection. Here, we present the identification of 200 approved drugs, appropriate for repurposing against COVID-19. We constructed a SARS-CoV-2-induced protein network, based on disease signatures defined by COVID-19 multiomics datasets, and cross-examined these pathways against approved drugs. This analysis identified 200 drugs predicted to target SARS-CoV-2-induced pathways, 40 of which are already in COVID-19 clinical trials, testifying to the validity of the approach. Using artificial neural network analysis, we classified these 200 drugs into nine distinct pathways, within two overarching mechanisms of action (MoAs): viral replication (126) and immune response (74). Two drugs (proguanil and sulfasalazine) implicated in viral replication were shown to inhibit replication in cell assays. This unbiased and validated analysis opens new avenues for the rapid repurposing of approved drugs into clinical trials.

摘要

严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的全球爆发需要迅速开发针对 2019 年冠状病毒病 (COVID-19) 感染的新疗法。在这里，我们确定了 200 种已批准的药物，这些药物适合重新用于治疗 COVID-19。我们基于 COVID-19 多组学数据集定义的疾病特征构建了一个 SARS-CoV-2 诱导的蛋白质网络，并将这些途径与已批准的药物进行交叉检查。该分析确定了 200 种预测可靶向 SARS-CoV-2 诱导途径的药物，其中 40 种已在 COVID-19 临床试验中，证明了该方法的有效性。使用人工神经网络分析，我们将这 200 种药物分为两种主要作用机制 (MoA) 内的九个不同途径：病毒复制 (126) 和免疫反应 (74)。两种被认为与病毒复制有关的药物（普乐津和柳氮磺胺吡啶）在细胞检测中被证明能抑制复制。这种无偏见和经过验证的分析为快速将已批准的药物重新用于临床试验开辟了新途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eee2/8245040/ceea40964a49/abh3032-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eee2/8245040/db230e94cf24/abh3032-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eee2/8245040/f571640ebd15/abh3032-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eee2/8245040/436582483fe9/abh3032-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eee2/8245040/8d6b885aa235/abh3032-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eee2/8245040/ceea40964a49/abh3032-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eee2/8245040/db230e94cf24/abh3032-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eee2/8245040/f571640ebd15/abh3032-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eee2/8245040/436582483fe9/abh3032-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eee2/8245040/8d6b885aa235/abh3032-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eee2/8245040/ceea40964a49/abh3032-f5.jpg

相似文献

1
Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies.鉴定 SARS-CoV-2 诱导的通路揭示了药物再利用策略。
Sci Adv. 2021 Jun 30;7(27). doi: 10.1126/sciadv.abh3032. Print 2021 Jun.
2
Identification of potential pan-coronavirus therapies using a computational drug repurposing platform.利用计算药物再利用平台鉴定潜在的泛冠状病毒治疗方法。
Methods. 2022 Jul;203:214-225. doi: 10.1016/j.ymeth.2021.11.002. Epub 2021 Nov 9.
3
SARS-CoV-2 replication and drug discovery.严重急性呼吸综合征冠状病毒 2 型复制与药物发现。
Mol Cell Probes. 2024 Oct;77:101973. doi: 10.1016/j.mcp.2024.101973. Epub 2024 Jul 24.
4
Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的网络分析和分子图谱绘制，以揭示药物靶点和临床开发药物的重新利用。
Virology. 2021 Mar;555:10-18. doi: 10.1016/j.virol.2020.12.006. Epub 2020 Dec 30.
5
Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.经 FDA 批准和正在研究的药物针对 SARS-CoV-2 刺突蛋白和主蛋白酶的再利用潜力，以及通过机器学习算法进行验证。
Chem Biol Drug Des. 2021 Apr;97(4):836-853. doi: 10.1111/cbdd.13812. Epub 2020 Dec 22.
6
Transcription-based drug repurposing for COVID-19.基于转录的 COVID-19 药物再利用。
Virus Res. 2020 Dec;290:198176. doi: 10.1016/j.virusres.2020.198176. Epub 2020 Sep 25.
7
Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.具有体外抗病毒活性和免疫调节作用的半胱胺有可能成为治疗 COVID-19 的重新定位药物候选物。
Cells. 2021 Dec 24;11(1):52. doi: 10.3390/cells11010052.
8
Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses .Stenoparib，一种细胞多聚（ADP-核糖）聚合酶抑制剂，可阻断 SARS-CoV-2 和 HCoV-NL63 人类冠状病毒的复制。
mBio. 2021 Jan 19;12(1):e03495-20. doi: 10.1128/mBio.03495-20.
9
Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.药物、代谢物和肺内蓄积的小溶酶体靶向小分子：多靶点抑制阻碍 SARS-CoV-2 感染和 COVID-19 进展。
Int J Mol Sci. 2021 Feb 11;22(4):1797. doi: 10.3390/ijms22041797.
10
Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 and SARS-CoV .食品和药物管理局批准的药物对 SARS-CoV-2 和 SARS-CoV 的广谱抗病毒活性。
J Virol. 2020 Oct 14;94(21). doi: 10.1128/JVI.01218-20.

引用本文的文献

1
Metabolism-associated protein network constructing and host-directed anti-influenza drug repurposing.代谢相关蛋白网络构建与宿主导向性抗流感药物的重新利用
Brief Bioinform. 2025 May 1;26(3). doi: 10.1093/bib/bbaf163.
2
Advancing curation of viral life cycles, host interactions, and therapeutics in Reactome.推进Reactome中病毒生命周期、宿主相互作用及治疗方法的管理。
J Virol. 2025 May 20;99(5):e0202424. doi: 10.1128/jvi.02024-24. Epub 2025 Apr 23.
3
Drug Repurposing for COVID-19 by Constructing a Comorbidity Network with Central Nervous System Disorders.

本文引用的文献

1
On the origin and continuing evolution of SARS-CoV-2.关于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的起源及持续进化
Natl Sci Rev. 2020 Jun;7(6):1012-1023. doi: 10.1093/nsr/nwaa036. Epub 2020 Mar 3.
2
Network medicine framework for identifying drug-repurposing opportunities for COVID-19.用于识别新冠病毒药物再利用机会的网络医学框架。
Proc Natl Acad Sci U S A. 2021 May 11;118(19). doi: 10.1073/pnas.2025581118.
3
The COVID-19 Drug and Gene Set Library.新冠病毒药物与基因集文库
利用构建包含中枢神经系统疾病的合并症网络来进行针对 COVID-19 的药物再利用。
Int J Mol Sci. 2024 Aug 16;25(16):8917. doi: 10.3390/ijms25168917.
4
Generic model to unravel the deeper insights of viral infections: an empirical application of evolutionary graph coloring in computational network biology.通用模型揭示病毒感染的更深层次见解：进化图着色在计算网络生物学中的实证应用。
BMC Bioinformatics. 2024 Feb 16;25(1):74. doi: 10.1186/s12859-024-05690-0.
5
Random walk with restart on multilayer networks: from node prioritisation to supervised link prediction and beyond.多层网络上的重启动随机游走：从节点优先级排序到有监督链路预测及更多。
BMC Bioinformatics. 2024 Feb 14;25(1):70. doi: 10.1186/s12859-024-05683-z.
6
Signaling network analysis reveals fostamatinib as a potential drug to control platelet hyperactivation during SARS-CoV-2 infection.信号转导网络分析表明，福他替尼可能是一种控制 SARS-CoV-2 感染期间血小板过度激活的潜在药物。
Front Immunol. 2023 Dec 21;14:1285345. doi: 10.3389/fimmu.2023.1285345. eCollection 2023.
7
How Deep Learning in Antiviral Molecular Profiling Identified Anti-SARS-CoV-2 Inhibitors.抗病毒分子谱分析中的深度学习如何识别抗SARS-CoV-2抑制剂。
Biomedicines. 2023 Nov 24;11(12):3134. doi: 10.3390/biomedicines11123134.
8
Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies.基于脒基糖的糖苷酶抑制剂的开发：通过分子建模和体外研究作为 SARS-CoV-2 病毒的药物候选物。
J Enzyme Inhib Med Chem. 2024 Dec;39(1):2289007. doi: 10.1080/14756366.2023.2289007. Epub 2023 Dec 12.
9
Network-based drug repurposing for HPV-associated cervical cancer.基于网络的人乳头瘤病毒相关宫颈癌药物重定位研究
Comput Struct Biotechnol J. 2023 Oct 19;21:5186-5200. doi: 10.1016/j.csbj.2023.10.038. eCollection 2023.
10
Antiviral Activity Against SARS-CoV-2 Variants Using in Silico and in Vitro Approaches.使用计算和体外方法对抗 SARS-CoV-2 变体的抗病毒活性。
J Microbiol. 2023 Jul;61(7):703-711. doi: 10.1007/s12275-023-00062-4. Epub 2023 Jun 26.
Patterns (N Y). 2020 Sep 11;1(6):100090. doi: 10.1016/j.patter.2020.100090. Epub 2020 Jul 25.
4
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity.木瓜蛋白酶样蛋白酶调节新型冠状病毒2的病毒传播和固有免疫。
Nature. 2020 Nov;587(7835):657-662. doi: 10.1038/s41586-020-2601-5. Epub 2020 Jul 29.
5
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.通过大规模化合物重新利用发现抗 SARS-CoV-2 病毒药物。
Nature. 2020 Oct;586(7827):113-119. doi: 10.1038/s41586-020-2577-1. Epub 2020 Jul 24.
6
Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing.探索 SARS-CoV-2 病毒-宿主-药物相互作用组以进行药物再利用。
Nat Commun. 2020 Jul 14;11(1):3518. doi: 10.1038/s41467-020-17189-2.
7
Lessons from dermatology about inflammatory responses in Covid-19.皮肤科在新冠病毒炎症反应中的启示。
Rev Med Virol. 2020 Sep;30(5):e2130. doi: 10.1002/rmv.2130. Epub 2020 Jul 12.
8
Extrapulmonary manifestations of COVID-19.COVID-19 的肺外表现。
Nat Med. 2020 Jul;26(7):1017-1032. doi: 10.1038/s41591-020-0968-3. Epub 2020 Jul 10.
9
The Global Phosphorylation Landscape of SARS-CoV-2 Infection.新冠病毒感染的全球磷酸化组景观。
Cell. 2020 Aug 6;182(3):685-712.e19. doi: 10.1016/j.cell.2020.06.034. Epub 2020 Jun 28.
10
COVID-19 revisiting inflammatory pathways of arthritis.COVID-19 再次审视关节炎的炎症通路。
Nat Rev Rheumatol. 2020 Aug;16(8):465-470. doi: 10.1038/s41584-020-0451-z. Epub 2020 Jun 19.